CA2323782A1 - Methodes de prevention et de traitement du cancer - Google Patents

Methodes de prevention et de traitement du cancer Download PDF

Info

Publication number
CA2323782A1
CA2323782A1 CA002323782A CA2323782A CA2323782A1 CA 2323782 A1 CA2323782 A1 CA 2323782A1 CA 002323782 A CA002323782 A CA 002323782A CA 2323782 A CA2323782 A CA 2323782A CA 2323782 A1 CA2323782 A1 CA 2323782A1
Authority
CA
Canada
Prior art keywords
vitamin
cells
hydroxylase
hydroxyvitamin
gene expressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002323782A
Other languages
English (en)
Inventor
Gary G. Schwartz
Balakrishna L. Lokeshwar
Tai C. Chen
Lyman W. Whitlatch
Xiang Fu Kong
Michael F. Holick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CUTANOGEN Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2323782A1 publication Critical patent/CA2323782A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13126—Vitamin D3 24-hydroxylase (1.14.13.126)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)

Abstract

L'invention concerne des méthodes permettant d'inhiber la croissance des cellules cancéreuses. Selon un mode de réalisation, la méthode consiste à accroître la quantité de précurseur métabolique de 1,25-dihydroxyvitamine D ("1,25(OH)¿2?D") ou d'un analogue ou d'un dérivé de ladite vitamine pouvant être utilisée par une cellule cible. Selon un mode de réalisation préféré, le précurseur est 25-hydroxyvitamine D. Selon un autre mode de réalisation, la méthode consiste à administrer à une cellule cible un gène codant pour 25-hydroxyvitamine D-1.alpha.-hydroxylase ("1.alpha.-OHase") avec ou sans gène codant pour le récepteur de la vitamine D de manière à accroître la production de 1,25(OH)¿2?D ou d'un analogue de cette vitamine à l'intérieur de la cellule cible, ce qui permet d'inhiber la prolifération cellulaire. Selon un autre mode de réalisation de l'invention, on utilise la méthode consistant à administrer à une cellule ou à des tissus cible un gène codant pour 1.alpha.-OHase avec ou sans gène codant pour le récepteur de la vitamine D, dans le traitement des troubles liés à une hyperprolifération cellulaire, des troubles de la pousse des cheveux, et des troubles du métabolisme osseux et calcique chez les animaux.
CA002323782A 1998-03-25 1999-03-25 Methodes de prevention et de traitement du cancer Abandoned CA2323782A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US4791898A 1998-03-25 1998-03-25
US09/047,918 1998-03-25
US12226899P 1999-03-01 1999-03-01
US12227099P 1999-03-01 1999-03-01
US60/122,268 1999-03-01
US60/122,270 1999-03-01
US12367099P 1999-03-09 1999-03-09
US12366999P 1999-03-09 1999-03-09
US60/123,669 1999-03-09
US60/123,670 1999-03-09
PCT/US1999/006491 WO1999049027A1 (fr) 1998-03-25 1999-03-25 Methodes de prevention et de traitement du cancer

Publications (1)

Publication Number Publication Date
CA2323782A1 true CA2323782A1 (fr) 1999-09-30

Family

ID=27535028

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002323782A Abandoned CA2323782A1 (fr) 1998-03-25 1999-03-25 Methodes de prevention et de traitement du cancer

Country Status (5)

Country Link
EP (1) EP1066377A1 (fr)
JP (1) JP2002507415A (fr)
CN (1) CN1301298A (fr)
CA (1) CA2323782A1 (fr)
WO (1) WO1999049027A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538037B2 (en) 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6566353B2 (en) 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
JPH1175863A (ja) 1997-07-10 1999-03-23 Kyowa Hakko Kogyo Co Ltd ２５−ヒドロキシビタミンＤ３−１α−水酸化酵素および該酵素をコードするＤＮＡ
WO2005101022A2 (fr) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Methodes diagnostiques et therapeutiques destinees aux maladies associees au recepteur 1 de la vitamine d (1,25-dihydroxyvitamine d3) (vdr1)
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
ES2593047T3 (es) 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
ES2670029T3 (es) * 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
WO2011123476A1 (fr) 2010-03-29 2011-10-06 Cytochroma Inc. Procédés et compositions pour réduction de taux d'hormone parathyroïde
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN105030791B (zh) * 2015-06-26 2017-12-22 张雷 25羟基维生素d在治疗颅内良性脑肿瘤中的应用
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues

Also Published As

Publication number Publication date
JP2002507415A (ja) 2002-03-12
WO1999049027A1 (fr) 1999-09-30
EP1066377A1 (fr) 2001-01-10
CN1301298A (zh) 2001-06-27

Similar Documents

Publication Publication Date Title
CA2323782A1 (fr) Methodes de prevention et de traitement du cancer
Whitlatch et al. 25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer
Gallegos et al. Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium
Gray et al. Hyperinsulinemia precedes insulin resistance in mice lacking pancreatic β-cell leptin signaling
Aono et al. Therapeutic effects of anti‐FGF23 antibodies in hypophosphatemic rickets/osteomalacia
Chen et al. Prostatic 25‐hydroxyvitamin D‐1α‐hydroxylase and its implication in prostate cancer
Miller et al. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha, 25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines.
US9308192B2 (en) Use of NRF2 inducers to treat epidermolysis bullosa simplex and related diseases
Hewison et al. 1alpha-Hydroxylase and the action of vitamin D
AU2024201048A1 (en) Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure
Ly et al. Transplasma membrane electron transport: enzymes involved and biological function
US20040087559A1 (en) Methods for prevention and treatment of cancer
MX2008015657A (es) Polipeptidos de factor de crecimiento similares a insulina estabilizados.
Beckett et al. 3 The iodothyronine deiodinases and 5′-deiodination
Sudhahar et al. Copper transporter ATP7A protects against endothelial dysfunction in type 1 diabetic mice by regulating extracellular superoxide dismutase
Hainault et al. Differential regulation of adipose tissue glucose transporters in genetic obesity (fatty rat). Selective increase in the adipose cell/muscle glucose transporter (GLUT 4) expression.
Rowe et al. Candidate 56 and 58 kDa protein (s) responsible for mediating the renal defects in oncogenic hypophosphatemic osteomalacia
Portale et al. Human 25-hydroxyvitamin D-1α-hydroxylase: cloning, mutations, and gene expression
Hedlund et al. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion.
WO2004039832A2 (fr) Peptides associes a la leptine
Huang et al. Targeted disruption of the 25-hydroxyvitamin D3 1α-hydroxylase gene in ras-transformed keratinocytes demonstrates that locally produced 1α, 25-dihydroxyvitamin D3 suppresses growth and induces differentiation in an autocrine fashion
Bai et al. Early lethality in Hyp mice with targeted deletion of Pth gene
Donkena et al. Vitamin d, sunlight and prostate cancer risk
Reddy et al. Lens-specific regulation of the thioredoxin-1 gene, but not thioredoxin-2, upon in vivo photochemical oxidative stress in the Emory mouse
US7033996B2 (en) Method for the treatment of vitamin D related disease

Legal Events

Date Code Title Description
FZDE Dead